Session

Making more of prostate biopsies

Poster Session 49

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     C. Beisland, Bergen (NO)
     C. Surcel, Bucharest (RO)
     G. Van Leenders, Rotterdam (NL)
  • Aims and objectives of this session

    To address the role of prostatic biopsies in the diagnosis of early prostate cancer, how to make use of their diagnostic and prognostic value in clinical decision making, and how to improve their diagnostic yield.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
608
Needle disinfectant technique during prostate biopsy is associated with less infection-related hospitalization: Results from a surgical collaborative

By: Ghani K.1, Auffenberg G.1, Brachulis A.1, Linsell S.1, Gao Y.1, Ye Z.1, Kraklau D.2, Montie J.1, Miller D.1

Institutes: 1University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2Lakeland Health, Dept. of Urology, St Joseph, United States of America

609
Are all pathologic Gleason scores 8 created equal? Implications for the applicability of new prostate cancer grading system

By: Gandaglia G.1, Fossati N.2, Bianchi M.3, Freschi M.4, Doglioni C.4, Farina E.2, Gallina A.2, Stabile A.2, Capitanio U.2, Salonia A.2, Montorsi F.2, Briganti A.2

Institutes: 1Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 3Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 4IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

610
Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy

By: Qi R., Moul J.

Institutes: Duke University Medical Center, Dept. of Urologic Surgery and Duke Cancer Institute, Durham, United States of America

611
Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy

By: Kweldam C.F.1, Kümmerlin I.P.1, Nieboer D.2, Verhoef E.I.1, Steyerberg E.W.2, Van Der Kwast T.H.3, Roobol M.J.4, Van Leenders G.J.L.H.1

Institutes: 1Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, 3University Health Network, Laboratory Medicine Program, Toronto, Canada, 4Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

613
An improved clinical risk stratification system to better predict cancer specific mortality at diagnosis in primary non-metastatic prostate cancer

By: Gnanapragasam V.1, Lophatananon A.2, Muir K.3, Gavin A.4, Wright K.5, Greenberg D.5

Institutes: 1University of Cambridge, Dept. of Academic Urology, Cambridge, United Kingdom, 2University of Warwick, Dept. of Health Science, Warwick, United Kingdom, 3University of Manchester, Dept. of Public Health, Manchester, United Kingdom, 4Queen’s University Belfast, Northern Ireland Cancer Registry, Belfast, United Kingdom, 5Public Health England, Cambridge, United Kingdom

614
Morphological and molecular pathway-based analysis of Gleason score 7 prostate cancer using a 17-gene expression assay

By: Bonham M.1, McCullough D.2, Lu R.2, Bennet J.3, Febbo P.4, Tsiatis A.5

Institutes: 1Genomic Health, Dept of Pathology, Redwood City, United States of America, 2Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, 3Genomic Health, Dept. of Data Management, Redwood City, United States of America, 4Genomic Health, Dept. of Translational Sciences, Redwood City, United States of America, 5Genomic Health, Dept. of Pathology, Redwood City, United States of America

615
Pathological outcomes after radical prostatectomy in men eligible for active surveillance, multi-institutional study

By: Mizuno K.1, Inoue T.2, Kinoshita H.3, Yano T.4, Kawanishi H.5, Kanda H.6, Terada N.2, Kamba T.2, Okumura K.5, Kawakita M.4, Ogura K.1, Sugimura Y.6, Matsuda T.3, Ogawa O.2

Institutes: 1Japanese Red Cross Otsu Hospital, Dept. of Urology, Otsu, Japan, 2Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, 3Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, 4Kobe Medical Center General Hospital, Dept. of Urology, Kobe, Japan, 5Tenri Hospital, Dept. of Urology, Tenri, Japan, 6Mie University Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan

616
Routine use of magnetic resonance imaging in prostate cancer facilitates better candidate selection for active surveillance

By: Sivaraman A., Ahallal Y., Sanchez-Salas R., Barret E., Linares Ospinos E., Perez Regetti J., Russo A., Armando Hernandez Palacios G., Galiano M., Rozet F., Cathelineau X.

Institutes: Institute Mutualiste Montsouris, Dept. of Urology, Paris, France

617
The value of PSA density in combination with PI-RADS scoring for prostate cancer prediction

By: Distler F.1, Radtke J.P.1, Bonekamp D.2, Roethke M.2, Schlemmer H-P.2, Roth W.3, Hohenfellner M.1, Hadaschik B.A.1

Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2German Cancer Research Center, Heidelberg, Dept. of Radiology, Heidelberg, Germany, 3University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany

618
Impact of targeted prostate biopsy using magnetic resonance imaging – ultrasound elastic fusion in men with suspicion of prostate cancer

By: Fourcade A.1, Perrouin-Verbe M-A.1, Tissot V.2, Serey-Effeil S.1, Callerot P.1, Cuvelier G.3, Coquet J-B.4, Doucet L.5, Delage F.4, Deruelle C.4, Joulin V.4, Fournier G.4, Valéri A.4

Institutes: 1University Hospital Of Brest, Department of Urology, Brest, France, 2University Hospital Of Brest, Department of Radiology, Brest, France, 3Hospital of Quimper, Department of Urology, Brest, France, 4University Hospital of Brest, Department of Urology, Brest, France, 5University Hospital of Brest, Department of Anatomo-Pathology, Brest, France

619
A non-inferiority multicentric controlled trial comparing three MRI-TRUS targeted biopsies to systematic TRUS biopsies for the detection of prostate cancer in patients with a single suspicious focus on prostate MRI: Results of the MURIELLE study

By: Delongchamps N.B.1, Portalez D.2, Bruguière E.3, Escourrou C.1, Casanova J.M.4, Roumiguié M.5, Hohn N.6, Bratan F.7, Sanzalone T.7, Rouvière O.7, Fiard G.6, Thoulouzan M.5, Malavaud B.5, Bordier B.3, Guillotreau J.3, Bouazza N.1, De Gorski A.8, Mozer P.8, Aziza R.9, Renard-Penna R.8, Misrai V.3, Descotes J.L.6, Cornud F.1

Institutes: 1Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 2Rangueil University Hospital, Dept. of Radiology, Toulouse, France, 3Clinique Pasteur, Dept. of Urology, Toulouse, France, 4Clinique Saint Jean de Dieu, Dept. of Urology, Paris, France, 5Rangueil University Hospital, Dept. of Urology, Toulouse, France, 6Grenoble University Hospital, Dept. of Urology, Grenoble, France, 7Hospices Civils de Lyon, Edouard Herriot Hospital, University Lyon 1, Dept. of Urinary and Vascular Radiology, Lyon, France, 8Pitié Salpêtrière University Hospital, Pierre et Marie Curie University, Dept. of Urology, Paris, France, 9Institut Universitaire du Cancer de Toulouse – Oncopole, Dept. of Urology, Toulouse, France

Summary and context
 G. Van Leenders, Rotterdam (NL)